Global Adoptive Cell Therapy Market, by Type (CAR-T, TCR-T, NK, and TIL), By Application (Lymphoma, Leukemia, and Others), by End User (Hospitals and Cancer Treatment Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 4,932.5 Mn in 2022 and is expected to exhibit a CAGR of 21.5% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key trends in the market include key players in the market focusing on growth strategies such as agreements, which is expected to drive growth over the forecast period. For instance, in January 2022, Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines announced that the company entered into an agreement with the National Cancer Institution (NCI), an institute of the National Institutes of Health (NIH), for worldwide exclusive commercial rights to the NIH’s CD22 chimeric antigen receptor (CAR) with a fully-human binder for use in certain Vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.
Global Adoptive Cell Therapy Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, contract research organizations, and other organizations that support drug development shifted to remote working environments. Recently, the U.S. Food and Drug Administration (FDA) guidance (March 2020 and updated on July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or include novel ways for conducting clinical trials in place of current protocols. Therefore, there are now more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-traditional approaches that do not involve in-person visits. Moreover, regulatory bodies are focusing on imposing the guidelines to prevent the spread of COVID-19 infection while conducting clinical trials on participants/subjects
According to the U.S. Food Drug and Administration report 2020, clinical trials performed by the companies and research institutes during the COVID-19 should follow the guidelines prescribed by the U.S. FDA , which are as follows: The participants in the clinical trials should undergo COVID-19 screening procedures to avoid the spread of COVID-19 infections during clinical trials, The participants are not allowed to visit the investigational site, and sponsors should evaluate alternative methods for contacting the participants/subjects through various methods such as phone contact, virtual visit, alternative location for assessment, including local labs or imaging centers and the sponsors should plan the visit of the participants to the investigational site to avoid the spread of COVID-19 infection. Moreover, to study the impact of COVID-19 on clinical trial studies on drugs, various research institutes are conducting survey studies to understand the impact of COVID-19 on ongoing clinical trials, globally. For instance, on April 23, 2020, Medidata technology and solutions, a global platform that supports clinical trials, performed an electronic (video conference) survey of 9,952 staff at various trial investigator sites, globally. The survey had a low response rate of 10.3%, as only few respondents answered the survey in a total of 1,030 participants. Most of the respondents in the survey were from the U.S. (North America; 58.3%), followed by Asia Pacific (23.8%), Europe (8.1%), South & Central America (7.1%), and Middle East & Africa (2.7%). The respondents included in the study were study coordinators, investigators, site managers/directors, clinical nurses, and others. The survey results showed that the ability to conduct ongoing clinical trials during the COVID-19 pandemic had affected 69%, whereas 78% mentioned that this situation affected the initiation of new trials.
Browse 29 Market Data Tables and 33 Figures spread through 186 Pages and in-depth TOC on “Global Adoptive Cell Therapy Market”- Forecast to 2030, Global Adoptive Cell Therapy Market, by Type (CAR-T, TCR-T, NK, and TIL), By Application (Lymphoma, Leukemia, and Others), by End User (Hospitals and Cancer Treatment Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Adoptive Cell Therapy Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/adoptive-cell-therapy-market-4957
Moreover, increasing prevalence of cancer is also expected to aid in growth of the global adoptive cell therapy market over the forecast period. For instance, according to data published by National Center for Biotechnology Information in April 2021, stated that there were around 2.43 million prevalent cases of leukemia, with an age-standardized prevalence rate (ASPR) of 32.26 per 100,000 population in 2017, globally.
Key Takeaways of the Global Adoptive Cell Therapy Market:
- The global adoptive cell therapy market is expected to exhibit a CAGR of 21.5% during the forecast period due to increasing product approvals which is expected to drive the growth of the market. For instance, in January 2022, CASI Pharmaceuticals, Inc., a U.S. based biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to its partner Juventas Cell Therapy Ltd, a privately held biotechnology company, for CNCT19, an investigational CD-19 directed CAR-T therapy, for the treatment of patients with Acute Lymphoblastic Leukemia (ALL).
- In terms of Application, Lymphoma segment is estimated to hold largest market share in the global adoptive cell therapy market over the forecast period, owing to increasing product approvals for the treatment of Lymphoma. For instance, in June 2021, Fosun Kite Biotechnology is a joint venture of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, is a Chinese pharmaceutical company. and U.S. Kite Pharma is an American biotechnology company announced its autologous CD19-directed CAR-T cell therapy Axicabtagene Ciloleucel (FKC876) (axicabtagene ciloleucel) had been approved by China National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy
- Among regions, North America is estimated to hold a dominant position in the global adoptive cell therapy market in 2022 owing to key players in the market focusing on product approvals for adoptive cell therapy. For instance, in June 2021, NantKwest Inc., a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of company’s immune system using natural killer (NK) cells to treat cancer, infectious diseases, and other diseases, announced that the company’s t-haNK is a human-derived, allogeneic, natural killer cell line engineered to express a chimeric antigen receptor (CAR) targeting PD-L1, whose origins arise from NantKwest’s proprietary NK-92 (aNK) master cell bank, investigational new drug application (IND) had cleared US FDA review.
- Major players operating in the Global Adoptive Cell Therapy Market are Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs
